Concurrent Chemoradiotherapy Containing Paclitaxel and Cisplatin With/Without Tarceva in Locally Advanced Esophageal Carcinoma: a Randomized Phase III Multi-center Trial.
For the esophageal carcinoma in II~III stage, routine dosage of Paclitaxel and platinum
medicine chemotherapy concurrently radical radiotherapy is worthy to be studied. On this
base, we advanced approach the enlarged field radiotherapy and the intervention of Tarceva.
And we approach the therapeutic effect for this method theoretically, which may give a
further reasonable guidance for the clinical therapy.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
failure: death from any cause
five years after enrollment
Shixiu Wu, MD
1st affliated hospital of Wen Zhou Medical college
China: Ministry of Health
Shixiu - 1